SCHEMBL15620139

SCHEMBL15620139

CCCS(=O)(=O)Nc1cc(F)c(F)c(C(=O)c2ccc3ncc(OCCO)cc3c2)c1Cl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 15/20 0.42
MAP2K4 P45985 4/20 0.40
RIPK2 O43353 2/20 0.40
RAF1 P04049 2/20 0.40
KDR P35968 2/20 0.40
MAP2K2 P36507 2/20 0.40
TGFBR2 P37173 2/20 0.40
NEK2 P51955 2/20 0.40
MAP2K1 Q02750 2/20 0.40
TNK2 Q07912 2/20 0.40
MAP2K5 Q13163 2/20 0.40
PTK6 Q13882 2/20 0.40
NEK11 Q8NG66 2/20 0.40
MAP3K20 Q9NYL2 2/20 0.40
MAP4K5 Q9Y4K4 2/20 0.40
ABL1 P00519 2/20 0.40
BMPR1B O00238 1/20 0.40
PLK4 O00444 1/20 0.40
PIR O00625 1/20 0.40
AURKA O14965 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17046445 0.93 BRAF (0.48) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046478 0.91 BRAF (0.44) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046517 0.87 BRAF (0.41) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL14716170 0.87 BRAF (0.43) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046470 0.86 BRAF (0.46) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046453 0.85 BRAF (0.53) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046437 0.83 BRAF (0.40) BRAFABL1CYP2C19
SCHEMBL17046443 0.83 BRAF (0.46) BRAFMAP2K4RIPK2RAF1KDR
SCHEMBL17046432 0.83 BRAF (0.47) BRAFMAP2K4ABL1CYP2C9CYP2C19
SCHEMBL17046482 0.83 BRAF (0.61) BRAFMAP2K4RIPK2RAF1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150246885-A1 CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-09-03 US claimed
EP-2897618-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Neupharma, Inc. (US) 2015-07-29 EP claimed
WO-2014047648-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. (US) 2014-03-27 WO claimed
EP-2897618-B1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA INC (US) 2021-11-17 EP disclosed
CN-104812389-B Certain chemical entities, compositions, and methods 润新生物公司 2020-07-17 CN disclosed
US-10457641-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC. (US) 2019-10-29 US disclosed
US-20170334859-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2017-11-23 US disclosed
US-9688635-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC. (US) 2017-06-27 US disclosed
US-20150246885-A1 CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2015-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10457641-B2 Certain chemical entities, compositions, and methods BRAF, PIK3CA, PLK1 BRAF 1/4885MAP2K4 758/4885RIPK2 883/4885
US-20150246885-A1 CERTAIN CHEMICAL ENTITES, COMPOSITIONS, AND METHODS BRAF, AURKC, PLK1 BRAF 1/4885MAP2K4 1914/4885RIPK2 1987/4885
US-20170334859-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 BRAF 1/4885MAP2K4 758/4885RIPK2 883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.